Search

Displaying results 4361 - 4370 of 10000 in total
  1. Drug

    Platelet Lysate

    go.drugbank.com/drugs/DB15869
    Investigational

    [A220188] It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.

  2. Drug

    Methadyl acetate

    go.drugbank.com/drugs/DB01433
    ExperimentalIllicit

    It is used mainly in the treatment of narcotic dependence.

  3. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

  4. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. … The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.

  5. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    than BA in preclinical studies. … Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.

    Synonyms: AN-9
  6. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. … XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia.

  7. Drug

    Interferon beta-1b

    go.drugbank.com/drugs/DB00068
    ApprovedInvestigational

    Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

    Categories: Interferon Type I
  8. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself. … ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection.

  9. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

  10. Drug

    Niflumic acid

    go.drugbank.com/drugs/DB04552
    Investigational

    Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.